Innate Pharma S.A. (IPHA:NASDAQ) closed at $1.35 on November 3, 2026, down 3.60% on the day. The stock trades 50.2% below its 52-week high of $2.71 and 15.4% above its 52-week low of $1.17. Over the past year, it lost 26.3%. Innate Pharma S.A. is part of the Health Care sector.
In 252 trading sessions since October 31, 2025, IPHA closed higher on 98 days (39%). Its best day was May 14, 2026 (+64.39%) and its worst was August 14, 2026 (-14.00%). The stock moved 10% or more in a single session 10 times. It opened at least 5% above the previous day's high 5 times.
Innate Pharma SA is a clinical-stage biotechnology company. The company is engaged in discovering and developing first-in-class therapeutic antibodies that harness the innate immune system to improve cancer treatment and clinical outcomes for patients. It specializes in immuno-oncology, a new therapeutic field that is changing cancer treatment by mobilizing the power of the body's immune system to recognize and kill cancer cells. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies.
Find more stocks like IPHA with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.